title: [A case of non-alcoholic fatty liver disease (NAFLD) aggravated after treatment with raloxifene].
abstract: A 70-year-old woman presented with abnormal liver function test 3 months after the introduction of daily intake of raloxifene, a selective estrogen receptor modulator, for osteoporosis. She had a history of NAFLD, diabetes mellitus and depression. The ratio of the computed-tomographic value of the liver against that of the spleen decreased remarkably. Pathological examination of the liver biopsy revealed severe steatosis. We thought her NAFLD was aggravated by raloxifene and discontinued the drug. The liver function test results improved and the computed tomographic liver-spleen ratio rose. This is the second case report of NAFLD becoming aggravated after treatment with raloxifene. It still remains unclear how raloxifene affects liver. Monitoring liver function is recommended when treating with raloxifene.
authors.affiliation: Department of Gastroenterology, Nagano Chuo Hospital. m-matsumura@healthcoop-nagano.or.jp
authors.forename: Makiko
authors.initials: M
authors.lastname: Matsumura
authors.forename: Koichi
authors.initials: K
authors.lastname: Tashiro
authors.forename: Akihiro
authors.initials: A
authors.lastname: Miura
authors.forename: Takehiro
authors.initials: T
authors.lastname: Tajima
authors.forename: Ikuharu
authors.initials: I
authors.lastname: Kinoshita
authors.forename: Eigo
authors.initials: E
authors.lastname: Kojima
authors.forename: Akihiko
authors.initials: A
authors.lastname: Yoshizawa
mesh_terms: D000368:Aged; D005234:Fatty Liver / Q000503:physiopathology*; D005260:Female; D006801:Humans; D065626:Non-alcoholic Fatty Liver Disease; D010024:Osteoporosis / Q000188:drug therapy; D020849:Raloxifene Hydrochloride / Q000009:adverse effects*; D020845:Selective Estrogen Receptor Modulators / Q000009:adverse effects*
chemical_list: D020845:Selective Estrogen Receptor Modulators; D020849:Raloxifene Hydrochloride